Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

A Nanoelectronics-blood-based diagnostic biomarker for ME / CFS by Rahim Esfandyarpour, PhD and Ronald W. Davis, PhD, Stanford Collaboration

Dr. Ron Davis, OMF Scientific Advisory Board Director, explains the PNAS publication on the nanoneedle (April 29, 2019) A paper describing the nanoneedle was published in the Proceedings of the National Academy of Sciences. Ronald W. Davis, Ph.D. is the senior author. Rahim Esfandyarpour, Ph.D. is the lead author. The nanoneedle is a test that measures changes in immune cells with their blood plasma as a result of salt stress. Inside the nanoneedle, the immune cells interfere with a small electric current. The change in electrical activity is directly correlated with the health of the sample. The test, which is still in a pilot phase, is based on how a person’s immune cells respond to stress. With blood samples from 40 people — 20 with ME / CFS and 20 without — the test yielded precise results, accurately flagging all patients and none of the healthy individuals.

Click here to read the abstract and full publication on PNAS.

Click here to read the Stanford announcement.

Click here to read the Stanford press release.

Click here to read the UCI press release. Transcript: Ron Davis Nanoneedle publication video.

Click here to read the Journal of American Medical Association (JAMA) article.






This research has garnered great attention and has been shared in many publications including the following highlights:

Click here to read the article in the San Francisco Chronicle.

Click here to read the article in Medscape.

Click here to read the article on ProHealth.

Click here to read the article in HealthRising.

Click here to read the article in the Sacramento Bee.

Click here to read the article in the Daily Mail.

Click here to read the article in Stat.

Click here to read the article in the Mercury News.

Click here to read the article in the Daily Mail.

Click here to read the article in Medical News Today.

Click here to read the article in El Pias (Spanish.)

Click here to read the article in the Irish Examiner.

Click here to read the article in The Sun (UK).

Click here to read the article in Gizmodo (Australia).

Click here to read the article in Visir (Iceland.)

Click here to read the article by NIH.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669